Not Signed In - Positive Phase II Clinical Trial Results For Insomnia Drug
Sat, 13 May 2006 06:00 AM EST
... Neurogen Corporation(Nasdaq: NRGN) today announced top-line results of Phase II human testingin transient insomnia for the Company's internally discovered drugcandidate for insomnia, NG2-73. The primary endpoint of the study measuredthe efficacy of NG2-73 in reducing time to onset of persistent sleep in awell established clinical model of transient insomnia in healthy adults. [click link for full article] ...
Related Topics
- Clinical Trials
- Insomnia
- Tarceva
- Pharmacology
- Psychopharmacology
- Bevacizumab Injection
- Trastuzumab
- Drug Safety
- Prescription Drugs
- Urinalysis
- Nystatin and Triamcinolone
- Drug Side Effects
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Drug Abuse
- Drug Information
- Tb
- Clinical Growth Charts
- Prescription Drug Abuse
- Prescription Drugs Abuse
email this page
print this page
bookmark this page
feedback on this page
